• Zymeworks agreed to buy Theravance Biopharma for USD 17 per share in cash, valuing the equity at about USD 929 million.
• Holders also get a contingent value right for 80% of net proceeds from any ampreloxetine monetization over 10 years.
• The remaining 20% of any ampreloxetine proceeds would go to Zymeworks.
• The deal is expected to close in the second half of 2026, subject to shareholder approval and customary conditions.
• The price implies a 22% premium to the March 3, 2026 close, or 10% above the volume-weighted average since then.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theravance Biopharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606290600PR_NEWS_USPR_____SF93852) on June 29, 2026, and is solely responsible for the information contained therein.